Investors
News Releases
- December 1, 2023Annovis Bio Appoints Andrew Walsh as Vice President Finance
- November 27, 2023Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
- November 8, 2023Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- November 2, 2023Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
- October 31, 2023Annovis Bio Announces Pricing of $7.5 Million Public Offering
- October 30, 2023Annovis Bio Announces Launch of Proposed Public Offering
- October 30, 2023Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
- October 24, 2023Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
- October 12, 2023Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
- August 15, 2023Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top